Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
26 slides from Harmony Biosciences's conference presentation, Jan 12, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
Copyright © 2026 Harmony Biosciences. All rights reserved. 44th Annual J.P. Morgan Healthcare Conference JEFFREY M. DAYNO, MD January 13,2026 | San Francisco
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,
Slide 3: Strong Financial Profile; Phase 3 Programs On Track for Blockbuster Status
5 STRONG FINANCIAL PROFILE PHASE 3 PROGRAMS ON TRACK FOR BLOCKBUSTER STATUS
Slide 4: Pitolisant Franchise Strategy
PITOLISANT FRANCHISE STRATEGY
Slide 5: The Pitolisant Franchise: Grow, Extend and Expand Leadership
The Pitolisant Franchise: Grow, Extend and Expand Leadership by Addressing Unmet Patient Needs 1. Barateau et al., Dauvilliers, 2019; 2. Wang et al., 2023; 3. McCullough et al. Novel treatment options in narcolepsy, Chicago Rush Memorial Center - SLEEP 2019 Abstract; 4. Droogleever et al. (2012). Se
Slide 6: Extending and Expanding the Pitolisant Franchise to the Mid-2040s
Extending and Expanding the Pitolisant Franchise to the Mid-2040s • Two meaningfully differentiated product profiles building off WAKIX with anticipated PDUFA dates prior to LOE; utility patents filed to 2044 • Pursuing other indications (fatigue in narcolepsy, sleep inertia in idiopathic hypersomni
Slide 7: Grow, Extend, Expand: Pitolisant Franchise Strategy
GROW EXTEND EXPAND PITOLISANT FRANCHISE STRATEGY
Slide 8: 2026 Net Revenue Guidance $1.00B-1.04B
2026 Net Revenue Guidance $1.00B-1.04B 2026 NET REVENUE GUIDANCE WAKIX Net Revenue Growth 2020–2025 $160 $305 $438 $582 $715 $1B+ $0 $200 $400 $600 $800 $1,000 2020 2021 2022 2023 2024 2026 Guidance Net Revenue ($M) 20251 $868 On Track to Achieve $1B+ in Narcolepsy Alone 8 January 13, 2026 Harmony B
Slide 9: WAKIX Is One of the Most Successful Orphan/Rare Launches
WAKIX® Is One of the Most Successful Orphan/Rare Launches KEY TAKEAWAY After Six Years of Growth, Large Market Opportunity Remains 1. https://narcolepsynetwork.org/accessed Feb 2024 80,000 90,000 ~170,000 Diagnosed Narcolepsy Patients Undiagnosed Narcolepsy Population People Living With Narcolepsy i
Slide 10: Strong Commercial Engine Driving Continued Growth
Strong Commercial Engine Driving Continued Growth 10 January 13, 2026 Harmony Biosciences | J.P. Morgan Healthcare Conference | All rights reserved. Strong Foundation Recent Developments Implication Only non-scheduled treatment, unique MOA 6+ years clinical experience Unique & Familiar Many team mem
Slide 11: Grow, Extend, Expand: Pitolisant Franchise Strategy
GROW EXTEND EXPAND PITOLISANT FRANCHISE STRATEGY
Slide 12: Pitolisant GR: Fast-To-Market Strategy Based on Bioequivalence
Pitolisant GR: Fast-To-Market Strategy Based on Demonstration of Bioequivalence to WAKIX® Formulation Q1 2027 Anticipated PDUFA Date POSITIVE PIVOTAL BIOEQUIVALENCE STUDY DOSING OPTIMIZATION STUDY COMPLETED 100% of the patients (46/46) able to initiate pitolisant GR at the therapeutic dose,17.8mg, w
Slide 13: Grow, Extend, Expand: Pitolisant Franchise Strategy
GROW EXTEND EXPAND PITOLISANT FRANCHISE STRATEGY
Slide 14: Pitolisant HD: Enhanced Formulation, Differentiated Product Profile
Pitolisant HD: Enhanced Formulation, Differentiated Product Profile ENHANCED FORMULATION WITH OPTIMIZED PK PROFILE AND HIGHER DOSE Designed to address the need for greater efficacy in excessive daytime sleepiness (EDS) in patients with central disorders of hypersomnolence PROGRAMS TO PURSUE A DIFFER
Slide 15: Wakix
Wakix. pitolisanttablets
Slide 16: Robust Pipeline
ROBUST PIPELINE
Slide 17: Innovative Late-Stage Pipeline
Innovative Late-Stage Pipeline PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY FILING MARKETED PRODUCT WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) EDS in Narcolepsy (Pediatric) Prader-Willi Syndrome (PWS) Pitolisant Pitolisant Gastro-Resistant (GR) in Narcole
Slide 18: BP1.15205: Potential Best-In-Class Orexin Receptor Agonist
BP1.15205: Potential Best-In-Class Orexin 2 Receptor (OX2R) Agonist PRECLINICAL DATA PRESENTATION AT SLEEP AND WSC Single-oral dose administration of BP1.15205 in transgenic mice produced significant and dose-dependent increases in total wakefulness time and sleep latency at every dose tested beginn
Slide 19: EPX-100: Open-Label Extension Data in Dravet Syndrome
EPX-100: Safety and effectiveness data from ongoing OLE of the Phase 3 Dravet Syndrome (DS) study presented at AES 2025 CLINICALLY MEANINGFUL REDUCTION IN SEIZURES Median reduction of ~50% in countable motor seizure frequency per 28 days (CMS-28) in participants who had at least 6-month exposure to
Slide 20: EPX-100: One of Most Advanced 5-HT2 Agonist Programs in DEEs
EPX-100: One of Most Advanced 5-HT2 (Serotonin) Agonist Programs in DEEs 20 January 13, 2026 Harmony Biosciences | J.P. Morgan Healthcare Conference | All rights reserved. ESTABLISHED 5-HT2 (SEROTONIN) AGONIST MECHANISM OF ACTION MoA validated via the zebrafish model ONGOING PHASE 3 TRIAL IN LENNOX-
Slide 21: Path to Long-Term Value Creation Beyond 2026
Path to Long-Term Value Creation Beyond 2026 Pipeline Poised to Deliver Value Through Extension and Expansion of Pitolisant Franchise and Innovative Epilepsy Assets KEY TAKEAWAY 2027 Pitolisant GR PDUFA Pitolisant HD Phase 3 TLD in narcolepsy and idiopathic hypersomnia (IH) EPX-100 DS/LGS Phase 3 TL
Slide 22: Strong Financial Profile
STRONG FINANCIAL PROFILE
Slide 23: Driving Value for Shareholders Based on Strong Financial Profile
Driving Value for Shareholders Based on Strong Financial Profile CONSISTENT REVENUE GROWTH AND PROFITABILITY ON TRACK TO BLOCKBUSTER STATUS IN NARCOLEPSY SELF FUNDING ACROSS THE ENTERPRISE POISED FOR VALUE CREATION Year-Over-Year Revenue 21% 2024 20251 2026 GUIDANCE $714.7M $868M $1.0-1.04B 23 Janua
Slide 24: Strong Financial Profile; Phase 3 Programs On Track for Blockbuster Status
5 STRONG FINANCIAL PROFILE PHASE 3 PROGRAMS ON TRACK FOR BLOCKBUSTER STATUS
Slide 25: To deliver on our promise to patients and create value for shareholders
To deliver on our promise to patients and create value for shareholders
Slide 26: company/harmonybiosciences/ @harmonybio harmony_biosciences www.harmonybiosciences.com
company/harmonybiosciences/ @harmonybio harmony_biosciences www.harmonybiosciences.com
Harmony Biosciences Holdings — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix